Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of the fiscal period ended Thursday, June 30, 2022.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2022 (2022-06-30): -3.17%.
RETURN ON EQUITY (ROE)
N/A
RETURN ON EQUITY (ROE) AVG TTM
N/A
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
EUDA Health Holdings Limited
Market Cap
$32.50M
Return on Equity (ROE)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$32.36M
Return on Equity (ROE)
-120.40%
TTM Avg
-43.89%
3Y Avg
-83.08%
5Y Avg
-65.54%
Market Cap
$32.24M
Return on Equity (ROE)
-116.14%
TTM Avg
-228.74%
3Y Avg
113.10%
5Y Avg
76.03%
Market Cap
$33.30M
Return on Equity (ROE)
-248.21%
TTM Avg
-991.58%
3Y Avg
-655.25%
5Y Avg
-438.62%
Market Cap
$31.39M
Return on Equity (ROE)
N/A
TTM Avg
29.33%
3Y Avg
173.42%
5Y Avg
64.03%
Market Cap
$31.23M
Return on Equity (ROE)
-86.96%
TTM Avg
-27.78%
3Y Avg
5.60%
5Y Avg
57.54%
Market Cap
$30.89M
Return on Equity (ROE)
N/A
TTM Avg
10.32%
3Y Avg
-262.53%
5Y Avg
-267.00%
Market Cap
$34.22M
Return on Equity (ROE)
-238.24%
TTM Avg
203.84%
3Y Avg
55.01%
5Y Avg
16.87%
Market Cap
$34.50M
Return on Equity (ROE)
-44.50%
TTM Avg
-16.33%
3Y Avg
-36.34%
5Y Avg
-33.52%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| EUDA Health Holdings Limited (EUDA) | $32.50M | N/A | N/A | N/A | N/A |
| Context Therapeutics Inc. (CNTX)vs › | $32.36M | -120.40% | -43.89% | -83.08% | -65.54% |
| MIRA Pharmaceuticals, Inc. (MIRA)vs › | $32.24M | -116.14% | -228.74% | 113.10% | 76.03% |
| HeartBeam, Inc. (BEAT)vs › | $33.30M | -248.21% | -991.58% | -655.25% | -438.62% |
| BeyondSpring Inc. (BYSI)vs › | $31.39M | N/A | 29.33% | 173.42% | 64.03% |
| Baird Medical Investment Holdings Limited (BDMD)vs › | $31.23M | -86.96% | -27.78% | 5.60% | 57.54% |
| MDxHealth S.A. (MDXH)vs › | $30.89M | N/A | 10.32% | -262.53% | -267.00% |
| Aligos Therapeutics, Inc. (ALGS)vs › | $34.22M | -238.24% | 203.84% | 55.01% | 16.87% |
| Grace Therapeutics, Inc. (GRCE)vs › | $34.50M | -44.50% | -16.33% | -36.34% | -33.52% |
| CervoMed Inc. (CRVO)vs › | $29.44M | -132.18% | -94.77% | -38.62% | -46.78% |
ROE
N/A
ROA
-277.4%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2022-06-30 | -3.17% |
| 2022-03-31 | -0.90% |
| 2021-12-31 | -53.50% |
